{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:21:10Z","timestamp":1791937270543,"version":"4.3.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:00:00Z","timestamp":1740873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:00:00Z","timestamp":1740873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01098-w","type":"journal-article","created":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T05:54:38Z","timestamp":1740894878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Optimizing rabies mRNA vaccine efficacy via RABV-G structural domain screening and heterologous prime-boost immunization"],"prefix":"10.1038","volume":"10","author":[{"given":"Dongdong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaotian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liao","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanmei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,2]]},"reference":[{"key":"1098_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0378-1135(90)90141-H","volume":"23","author":"H Bourhy","year":"1990","unstructured":"Bourhy, H., Sureau, P. & Tordo, N. From rabies to rabies-related viruses. Vet. Microbiol. 23, 115\u2013128 (1990).","journal-title":"Vet. Microbiol."},{"key":"1098_CR2","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1128\/jvi.69.2.764-772.1995","volume":"69","author":"NB Ray","year":"1995","unstructured":"Ray, N. B., Ewalt, L. C. & Lodmell, D. L. Rabies virus replication in primary murine bone marrow macrophages and in human and murine macrophage-like cell lines: implications for viral persistence. J. Virol. 69, 764\u2013772 (1995).","journal-title":"J. Virol."},{"key":"1098_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/QCO.0000000000000420","volume":"31","author":"G Ugolini","year":"2018","unstructured":"Ugolini, G. & Hemachudha, T. Rabies: changing prophylaxis and new insights in pathophysiology. Curr. Opin. Infect. Dis. 31, 93\u2013101 (2018).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"1098_CR4","doi-asserted-by":"crossref","unstructured":"Davis, B. M., Rall, G. F., Schnell, M. J. Everything you always wanted to know about rabies virus (but were afraid to ask). Annu. Rev. Virol. 2, 451\u2013471 (2015)","DOI":"10.1146\/annurev-virology-100114-055157"},{"key":"1098_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrmicro.2018.11","volume":"16","author":"CR Fisher","year":"2018","unstructured":"Fisher, C. R., Streicker, D. G. & Schnell, M. J. The spread and evolution of rabies virus: conquering new frontiers. Nat. Rev. Microbiol. 16, 241\u2013255 (2018).","journal-title":"Nat. Rev. Microbiol."},{"key":"1098_CR6","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1073\/pnas.83.11.3914","volume":"83","author":"N Tordo","year":"1986","unstructured":"Tordo, N., Poch, O., Ermine, A., Keith, G. & Rougeon, F. Walking along the rabies genome: is the large G-L intergenic region a remnant gene? Proc. Natl Acad. Sci. USA 83, 3914\u20133918 (1986).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1098_CR7","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.1093\/emboj\/17.24.7250","volume":"17","author":"C Tuffereau","year":"1998","unstructured":"Tuffereau, C., Benejean, J., Blondel, D., Kieffer, B. & Flamand, A. Low-affinity nerve-growth factor receptor (P75NTR) can serve as a receptor for rabies virus. EMBO J. 17, 7250\u20137259 (1998).","journal-title":"EMBO J."},{"key":"1098_CR8","doi-asserted-by":"publisher","first-page":"7181","DOI":"10.1128\/JVI.72.9.7181-7190.1998","volume":"72","author":"MI Thoulouze","year":"1998","unstructured":"Thoulouze, M. I. et al. The neural cell adhesion molecule is a receptor for rabies virus. J. Virol. 72, 7181\u20137190 (1998).","journal-title":"J. Virol."},{"key":"1098_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/096876899294724","volume":"16","author":"Y Gaudin","year":"1999","unstructured":"Gaudin, Y. et al. Rabies virus-induced membrane fusion. Mol. Membr. Biol. 16, 21\u201331 (1999).","journal-title":"Mol. Membr. Biol."},{"key":"1098_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/v4010117","volume":"4","author":"AAV Albertini","year":"2012","unstructured":"Albertini, A. A. V., Baquero, E., Ferlin, A. & Gaudin, Y. Molecular and cellular aspects of rhabdovirus entry. Viruses 4, 117\u2013139 (2012).","journal-title":"Viruses"},{"key":"1098_CR11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1006\/viro.1993.1261","volume":"194","author":"A Flamand","year":"1993","unstructured":"Flamand, A., Raux, H., Gaudin, Y. & Ruigrok, R. W. Mechanisms of rabies virus neutralization. Virology 194, 302\u2013313 (1993).","journal-title":"Virology"},{"key":"1098_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/jvi.62.1.1-7.1988","volume":"62","author":"C Prehaud","year":"1988","unstructured":"Prehaud, C., Coulon, P., LaFay, F., Thiers, C. & Flamand, A. Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence. J. Virol. 62, 1\u20137 (1988).","journal-title":"J. Virol."},{"key":"1098_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3390\/v8110279","volume":"8","author":"SM Zhu","year":"2016","unstructured":"Zhu, S. M. & Guo, C. P. Rabies control and treatment: from prophylaxis to strategies with curative potential. Viruses 8, 279 (2016).","journal-title":"Viruses"},{"key":"1098_CR14","first-page":"765","volume":"101","author":"LC Pasteur","year":"1885","unstructured":"Pasteur, L.C. & Roux, E. Methode pour prevenir la rage apr\u00e8s morsue (in French). CR Acad. Sci. Paris 101, 765\u2013772 (1885).","journal-title":"CR Acad. Sci. Paris"},{"key":"1098_CR15","doi-asserted-by":"crossref","unstructured":"Natesan, K. et al. Developments in rabies vaccines: the path traversed from pasteur to the modern era of immunization. Vaccines. 21, 756 (2023).","DOI":"10.3390\/vaccines11040756"},{"key":"1098_CR16","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1016\/j.vaccine.2012.03.047","volume":"30","author":"S Finke","year":"2012","unstructured":"Finke, S., Karger, A., Freuling, C. & Mueller, T. Assessment of inactivated human rabies vaccines: biochemical characterization and genetic identification of virus strains. Vaccine 30, 3603\u20133609 (2012).","journal-title":"Vaccine"},{"key":"1098_CR17","first-page":"401","volume":"58","author":"P Atanasiu","year":"1981","unstructured":"Atanasiu, P., Perrin, P., Segre, L. & Manganas, O. Comparison of inactivated rabies vaccines obtained from diploid and polyploid heterologous cells (Hak, BHK, and Vero). Arch. Inst. Pasteur Tunis. 58, 401\u2013421 (1981).","journal-title":"Arch. Inst. Pasteur Tunis."},{"key":"1098_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1080\/21645515.2016.1229719","volume":"13","author":"M Tan","year":"2017","unstructured":"Tan, M. & Jiang, X. Recent advancements in combination subunit vaccine development. Hum. Vaccin. Immunother. 13, 180\u2013185 (2017).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1098_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1139\/cjm-2024-0023","volume":"70","author":"P-H Wang","year":"2024","unstructured":"Wang, P.-H. & Xing, L. The roles of rabies virus structural proteins in immune evasion and implications for vaccine development. Can. J. Microbiol. 70, 461\u2013469 (2024).","journal-title":"Can. J. Microbiol."},{"key":"1098_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.7774\/cevr.2016.5.2.159","volume":"5","author":"D-K Yang","year":"2016","unstructured":"Yang, D.-K. et al. Safety and immunogenicity of recombinant rabies virus (ERAGS) in mice and raccoon dogs. Clin. Exp. Vaccin. Res. 5, 159\u2013168 (2016).","journal-title":"Clin. Exp. Vaccin. Res."},{"key":"1098_CR21","doi-asserted-by":"publisher","first-page":"11300","DOI":"10.1073\/pnas.0905640106","volume":"106","author":"M Faber","year":"2009","unstructured":"Faber, M. et al. Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc. Natl Acad. Sci. USA 106, 11300\u201311305 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1098_CR22","doi-asserted-by":"crossref","unstructured":"Tao, L. et al. Generation of a recombinant rabies Flury LEP virus carrying an additional G gene creates an improved seed virus for inactivated vaccine production. Virol. J. 8, e87105 (2011).","DOI":"10.1186\/1743-422X-8-454"},{"key":"1098_CR23","doi-asserted-by":"crossref","unstructured":"Liu, X. et al. A recombinant rabies virus encoding two copies of the glycoprotein gene confers protection in dogs against a virulent challenge. PLoS One 9, e87105 (2014).","DOI":"10.1371\/journal.pone.0087105"},{"key":"1098_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11262-014-1049-9","volume":"48","author":"X-H Xue","year":"2014","unstructured":"Xue, X.-H. et al. An inactivated recombinant rabies CVS-11 virus expressing two copies of the glycoprotein elicits a higher level of neutralizing antibodies and provides better protection in mice. Virus Genes 48, 411\u2013420 (2014).","journal-title":"Virus Genes"},{"key":"1098_CR25","doi-asserted-by":"crossref","unstructured":"Yale, G. et al. Review of oral rabies vaccination of dogs and its application in India. Viruses-Basel. 14, 155 (2022).","DOI":"10.3390\/v14010155"},{"key":"1098_CR26","doi-asserted-by":"crossref","unstructured":"Maki, J. et al. Oral vaccination of wildlife using a vaccinia-rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG\u00ae): a global review. Vet. Res. 48, 57 (2017).","DOI":"10.1186\/s13567-017-0459-9"},{"key":"1098_CR27","doi-asserted-by":"publisher","first-page":"7214","DOI":"10.1016\/j.vaccine.2009.09.031","volume":"27","author":"MOV Osinubi","year":"2009","unstructured":"Osinubi, M. O. V. et al. Enhancing comparative rabies DNA vaccine effectiveness through glycoprotein gene modifications. Vaccine 27, 7214\u20137218 (2009).","journal-title":"Vaccine"},{"key":"1098_CR28","doi-asserted-by":"publisher","first-page":"8926","DOI":"10.1128\/JVI.00787-10","volume":"84","author":"L Tao","year":"2010","unstructured":"Tao, L. et al. Molecular basis of neurovirulence of flury rabies virus vaccine strains: importance of the polymerase and the glycoprotein R333Q mutation. J. Virol. 84, 8926\u20138936 (2010).","journal-title":"J. Virol."},{"key":"1098_CR29","doi-asserted-by":"crossref","unstructured":"Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S. & DeRosa, F. The promise of mRNA vaccines: a biotech and industrial perspective. Npj Vaccines. 5, 11 (2020).","DOI":"10.1038\/s41541-020-0159-8"},{"key":"1098_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41577-019-0243-3","volume":"20","author":"JR Mascola","year":"2020","unstructured":"Mascola, J. R. & Fauci, A. S. Novel vaccine technologies for the 21st century. Nat. Rev. Immunol. 20, 87\u201388 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1098_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.14740\/jocmr4490","volume":"13","author":"D Vasireddy","year":"2021","unstructured":"Vasireddy, D., Atluri, P., Malayala, S. V., Vanaparthy, R. & Mohan, G. Review of COVID-19 vaccines approved in the united states of america for emergency use. J. Clin. Med. Res. Can. 13, 204\u2013213 (2021).","journal-title":"J. Clin. Med. Res. Can."},{"key":"1098_CR32","first-page":"1","volume":"76","author":"S Amanpour","year":"2021","unstructured":"Amanpour, S. The rapid development and early success of Covid 19 vaccines have raised hopes for accelerating the cancer treatment mechanism. Arch. Razi Inst. 76, 1\u20136 (2021).","journal-title":"Arch. Razi Inst."},{"key":"1098_CR33","first-page":"111","volume":"440","author":"M-G Alameh","year":"2022","unstructured":"Alameh, M.-G., Weissman, D. & Pardi, N. Messenger RNA-based vaccines against infectious diseases. Curr. Top. Microbiol. Immunol. 440, 111\u2013145 (2022).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1098_CR34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","volume":"27","author":"G Maruggi","year":"2019","unstructured":"Maruggi, G., Zhang, C., Li, J., Ulmer, J. B. & Yu, D. mRNA as a transformative technology for vaccine development to control infectious diseases. Mol. Ther. 27, 757\u2013772 (2019).","journal-title":"Mol. Ther."},{"key":"1098_CR35","doi-asserted-by":"crossref","unstructured":"Wang, Y. et al. mRNA vaccine: a potential therapeutic strategy. Mol Cancer. 20, 33 (2021).","DOI":"10.1186\/s12943-021-01311-z"},{"key":"1098_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines - a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1098_CR37","doi-asserted-by":"crossref","unstructured":"Fang, Z., Yu, P. & Zhu, W. Development of mRNA rabies vaccines. Hum. Vaccin. Immunother. 20, 2382499 (2024).","DOI":"10.1080\/21645515.2024.2382499"},{"key":"1098_CR38","doi-asserted-by":"crossref","unstructured":"Barouch, D. H. Novel heterologous adenovirus prime-boost HIV-1 vaccine. Curr. Opin. HIV AIDS 5, 386\u2013390 (2008).","DOI":"10.1097\/COH.0b013e32833cfe4c"},{"key":"1098_CR39","doi-asserted-by":"crossref","unstructured":"Kim, J., Lee S.-H., Kim H.-H., Park J.-H. & Park C.-K. Heterologous prime-boost vaccination with commercial FMD vaccines elicits a broader immune response than homologous prime-boost vaccination in pigs. Vaccines. 11, 551 (2023).","DOI":"10.3390\/vaccines11030551"},{"key":"1098_CR40","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.idnow.2022.09.011","volume":"52","author":"O Launay","year":"2022","unstructured":"Launay, O. & Thill, P. Heterologous prime boost COVID 19 vaccination. Infect. Dis. Now. 52, S7\u2013S8 (2022).","journal-title":"Infect. Dis. Now."},{"key":"1098_CR41","doi-asserted-by":"crossref","unstructured":"Levine, M. Z. et al. Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-Glade antibody responses than homologous prime-boost. Npj Vaccines. 4, 22 (2019).","DOI":"10.1038\/s41541-019-0114-8"},{"key":"1098_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.188","volume":"3","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Mixed formulation of mRNA and protein-based COVID-19 vaccines triggered superior neutralizing antibody responses. MedComm 3, e188 (2022).","journal-title":"MedComm"},{"key":"1098_CR43","doi-asserted-by":"publisher","first-page":"8029","DOI":"10.2147\/IJN.S464720","volume":"19","author":"D Li","year":"2024","unstructured":"Li, D. et al. Heterologous prime-boost immunization strategies using varicella-zoster virus gE mRNA vaccine and adjuvanted protein subunit vaccine triggered superior cell immune response in middle-aged mice. Int. J. Nanomed. 19, 8029\u20138042 (2024).","journal-title":"Int. J. Nanomed."},{"key":"1098_CR44","first-page":"255","volume":"40","author":"TJ Wiktor","year":"1978","unstructured":"Wiktor, T. J. Cell-mediated immunity and postexposure protection from rabies by inactivated vaccines of tissue culture origin. Dev. Biol. Stand. 40, 255\u2013264 (1978).","journal-title":"Dev. Biol. Stand."},{"key":"1098_CR45","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.4049\/jimmunol.141.8.2721","volume":"141","author":"E Celis","year":"1988","unstructured":"Celis, E., Karr, R. W., Dietzschold, B., Wunner, W. H. & Koprowski, H. Genetic restriction and fine specificity of human T cell clones reactive with rabies virus. J. Immunol. 141, 2721\u20132728 (1988).","journal-title":"J. Immunol."},{"key":"1098_CR46","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1128\/JVI.76.7.3374-3381.2002","volume":"76","author":"M Faber","year":"2002","unstructured":"Faber, M. et al. Overexpression of the rabies virus, glycoprotein results in enhancement of apoptosis and antiviral immune response. J. Virol. 76, 3374\u20133381 (2002).","journal-title":"J. Virol."},{"key":"1098_CR47","doi-asserted-by":"crossref","unstructured":"Bai, S. et al. A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice. Front. Immunol. 13, 1099991 (2023).","DOI":"10.3389\/fimmu.2022.1099991"},{"key":"1098_CR48","doi-asserted-by":"crossref","unstructured":"Long, J. et al. A rabies mRNA vaccine provides a rapid and long-term immune response in mice. Nano Today 53, 102038 (2023)","DOI":"10.1016\/j.nantod.2023.102038"},{"key":"1098_CR49","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.vaccine.2024.01.057","volume":"42","author":"H Cao","year":"2024","unstructured":"Cao, H. et al. A rabies mRNA vaccine with H270P mutation in its glycoprotein induces strong cellular and humoral immunity. Vaccine 42, 1116\u20131121 (2024).","journal-title":"Vaccine"},{"key":"1098_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.antiviral.2015.06.011","volume":"121","author":"L Shuai","year":"2015","unstructured":"Shuai, L. et al. Genetically modified rabies virus ERA strain is safe and induces long-lasting protective immune response in dogs after oral vaccination. Antivir. Res. 121, 9\u201315 (2015).","journal-title":"Antivir. Res."},{"key":"1098_CR51","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1016\/j.vaccine.2014.06.058","volume":"32","author":"P Koraka","year":"2014","unstructured":"Koraka, P. et al. A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice. Vaccine 32, 4644\u20134650 (2014).","journal-title":"Vaccine"},{"key":"1098_CR52","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1348-0421.2005.tb03664.x","volume":"49","author":"K Thirapanmethee","year":"2005","unstructured":"Thirapanmethee, K., Ootaki, N., Sakai, M., Lien, C. K. & Kawai, A. Further studies on the soluble form (Gs) of rabies virus glycoprotein (G): Molecular structure of Gs protein and possible mechanism of the shedding. Microbiol. Immunol. 49, 733\u2013743 (2005).","journal-title":"Microbiol. Immunol."},{"key":"1098_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-017-0789-2","volume":"14","author":"H-H Kim","year":"2017","unstructured":"Kim, H.-H., Yang, D.-K., Nah, J.-J., Song, J.-Y. & Cho, I.-S. Comparison of the protective efficacy between single and combination of recombinant adenoviruses expressing complete and truncated glycoprotein, and nucleoprotein of the pathogenic street rabies virus in mice. Virol. J. 14, 122 (2017).","journal-title":"Virol. J."},{"key":"1098_CR54","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.7150\/ijms.87134","volume":"20","author":"Q Li","year":"2023","unstructured":"Li, Q. et al. Immunogenicity and antigenicity of the ectodomain of rabies virus glycoprotein stably expressed in HEK293T cells. Int. J. Med. Sci. 20, 1282\u20131292 (2023).","journal-title":"Int. J. Med. Sci."},{"key":"1098_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-022-01919-7","volume":"19","author":"J Li","year":"2022","unstructured":"Li, J. et al. An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs. Virol. J. 19, 184 (2022).","journal-title":"Virol. J."},{"key":"1098_CR56","doi-asserted-by":"publisher","first-page":"7129","DOI":"10.1016\/j.vaccine.2023.10.019","volume":"41","author":"Q Hongtu","year":"2023","unstructured":"Hongtu, Q., BoLi, L., Jianguo, C., Shusheng, P. & Ming, M. Immunogenicity of rabies virus G mRNA formulated with lipid nanoparticles and nucleic acid immunostimulators in mice. Vaccine 41, 7129\u20137137 (2023).","journal-title":"Vaccine"},{"key":"1098_CR57","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1080\/22221751.2022.2059404","volume":"11","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV. Emerg. Microbes Infect. 11, 1145\u20131153 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"1098_CR58","doi-asserted-by":"publisher","first-page":"2309985","DOI":"10.1080\/22221751.2024.2309985","volume":"13","author":"L Huang","year":"2024","unstructured":"Huang, L. et al. Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques. Emerg. Microbes Infect. 13, 2309985 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"1098_CR59","doi-asserted-by":"publisher","first-page":"e0004746","DOI":"10.1371\/journal.pntd.0004746","volume":"10","author":"M Schnee","year":"2016","unstructured":"Schnee, M. et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl. Trop. Dis. 10, e0004746 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1098_CR60","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.1016\/j.vaccine.2020.06.062","volume":"38","author":"MA Monslow","year":"2020","unstructured":"Monslow, M. A. et al. Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates. Vaccine 38, 5793\u20135802 (2020).","journal-title":"Vaccine"},{"key":"1098_CR61","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/vaccines9121440","volume":"9","author":"H Cao","year":"2021","unstructured":"Cao, H., Wang, Y., Luan, N., Lin, K. & Liu, C. Effects of varicella-zoster virus glycoprotein E carboxyl-terminal mutation on mRNA vaccine efficacy. Vaccines 9, 1440 (2021).","journal-title":"Vaccines"},{"key":"1098_CR62","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1016\/j.vaccine.2018.07.006","volume":"36","author":"W Shi","year":"2018","unstructured":"Shi, W. et al. Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants. Vaccine 36, 5020\u20135029 (2018).","journal-title":"Vaccine"},{"key":"1098_CR63","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2389115","volume":"13","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. A nucleoside-modified mRNA vaccine forming rabies virus-like particle elicits strong cellular and humoral immune responses against rabies virus infection in mice. Emerg. Microbes Infect. 13, 2389115 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"1098_CR64","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1186\/1743-422X-8-521","volume":"8","author":"W Jiao","year":"2011","unstructured":"Jiao, W. et al. Molecular characterization of China rabies virus vaccine strain. Virol. J. 8, 521 (2011).","journal-title":"Virol. J."},{"key":"1098_CR65","doi-asserted-by":"publisher","first-page":"13587","DOI":"10.3390\/ijms241713587","volume":"24","author":"H Zhao","year":"2023","unstructured":"Zhao, H. et al. Immune response of inactivated rabies vaccine inoculated via intraperitoneal, intramuscular, subcutaneous and needle-free injection technology-based intradermal routes in mice. Int. J. Mol. Sci. 24, 13587 (2023).","journal-title":"Int. J. Mol. Sci."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01098-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01098-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01098-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T17:29:08Z","timestamp":1740936548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01098-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,2]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1098"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01098-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5364324\/v1","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,2]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}